Key Points
- CEO Glendon French sold 41,882 Pulmonx shares at an average price of $2.26, generating approximately $94,653. The sale covered tax-withholding obligations tied to vested equity awards, and he retained 1.14 million shares.
- Pulmonx reported quarterly revenue of $22.76 million and an adjusted loss of $0.24 per share, beating analyst estimates, but remains unprofitable with a projected full-year loss of $1.05 per share.
- Analysts maintain an overall “Moderate Buy” rating, with three Buy ratings and one Sell rating and an average price target of $7.67, while institutional investors own about 91% of the stock.
Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) insider Geoffrey Rose sold 7,879 shares of Pulmonx stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $2.26, for a total transaction of $17,806.54. Following the completion of the transaction, the insider owned 449,832 shares in the company, valued at approximately $1,016,620.32. This trade represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Pulmonx Stock Down 0.9%
LUNG stock opened at $2.26 on Friday. The stock has a market capitalization of $97.07 million, a PE ratio of -1.95 and a beta of 0.34. The company has a fifty day moving average of $1.81 and a 200-day moving average of $1.56. The company has a debt-to-equity ratio of 0.95, a quick ratio of 3.52 and a current ratio of 4.32. Pulmonx Corporation has a one year low of $1.13 and a one year high of $2.89.
Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.04. The business had revenue of $22.76 million for the quarter, compared to analyst estimates of $22.39 million. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. As a group, analysts expect that Pulmonx Corporation will post -1.05 EPS for the current year.
Pulmonx News Summary
Here are the key news stories impacting Pulmonx this week:
- Positive Sentiment: Analysts maintain a generally favorable view of Pulmonx, with three Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $7.67. The company’s latest reported revenue of $22.76 million and loss of $0.24 per share also topped consensus estimates of $22.39 million and a $0.28-per-share loss. Pulmonx analyst and earnings information
- Neutral Sentiment: Four insiders—including CEO Glendon French III, General Counsel David Lehman, Geoffrey Rose and Srikanth Radhakrishnan—sold a combined 78,340 shares at approximately $2.26 per share. The filings state that the sales were made to cover tax-withholding obligations from vested equity awards, which reduces the likelihood that they signal a broad loss of confidence. The insiders still retain substantial holdings. Pulmonx insider sales report
- Neutral Sentiment: Institutional ownership remains high at approximately 91%, while several investment firms recently initiated small positions. These transactions may provide some ownership support but are not large enough, based on the available data, to materially change the near-term outlook. Pulmonx institutional ownership information
- Negative Sentiment: Recent gains appear to have prompted profit-taking, contributing to the stock’s retreat from its advance. Pulmonx shares fall following recent gains
- Negative Sentiment: Investor caution is heightened by Pulmonx’s “tepid” earnings outlook. The medical-device company remains loss-making, with analysts forecasting a full-year loss of approximately $1.05 per share, making sustained profitability and growth important catalysts for the stock. Pulmonx profit-taking and earnings outlook
Institutional Trading of Pulmonx
A number of institutional investors have recently bought and sold shares of the company. Cerity Partners LLC acquired a new stake in shares of Pulmonx in the fourth quarter valued at approximately $27,000. Opal Capital LLC purchased a new stake in Pulmonx in the 4th quarter valued at approximately $29,000. Lazard Asset Management LLC acquired a new stake in Pulmonx during the 4th quarter valued at $31,000. Jain Global LLC purchased a new position in Pulmonx during the third quarter worth $30,000. Finally, R Squared Ltd acquired a new position in shares of Pulmonx in the first quarter worth $26,000. 91.04% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
LUNG has been the subject of several recent analyst reports. Weiss Ratings raised Pulmonx from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 25th. Wall Street Zen upgraded Pulmonx from a "sell" rating to a "hold" rating in a research report on Saturday, June 27th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $7.67.
Check Out Our Latest Research Report on Pulmonx
About Pulmonx
(
Get Free Report)
Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company's flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.
The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
